Health

  • August 10, 2026

    HHS Denies Existence Of $150M Deal With Texas Firm To Rep Migrant Kids

    The U.S. Department of Health and Human Services said Monday that a small law firm in Houston had not yet been tapped for a sole-source grant worth up to $150 million to provide legal services to unaccompanied migrant children in government custody.

  • August 10, 2026

    Trump Revives Push To Reduce Kids' Vaccine Schedule

    Responding to a legal setback, President Donald Trump signed an executive order Monday recommending fewer vaccines for most children and calling on parents and doctors to space out the vaccines they do give.

  • August 10, 2026

    9th Circ. Backs FDA's Denial Of Fruit-, Candy-Flavored Vapes

    The Ninth Circuit on Monday affirmed the U.S. Food and Drug Administration's denial of Drip More LLC's applications to sell candy- and fruit-flavored vapes, saying the company didn't show those flavors provide an additional benefit to adult smokers that justifies the added risks that young people will use the products.

  • August 10, 2026

    ModivCare Execs Must Face Suit Over Cash Flow Woes

    A Colorado federal judge has declined to toss a shareholder class action against current and former executives of patient transportation company ModivCare Inc. over their alleged failure to disclose the negative impact of certain contract renegotiations, finding that the investors pled actionable misstatements.

  • August 10, 2026

    Clinics' Suit Over Fund Use Ballot Measure Gets Tossed

    A California federal judge tossed a suit that federally designated community health clinics filed to block the placement of an expenditure transparency reporting initiative on the November ballot, saying the clinics' claims aren't ripe for court review.

  • August 10, 2026

    AbbVie, Novartis Seek To Block Ill. 340B Drug Discount Law

    AbbVie Inc. and Novartis Pharmaceuticals are urging an Illinois federal court to block a state law that took effect Friday barring pharmaceutical manufacturers from trying to impose restrictions on 340B contract pharmacy arrangements, arguing in a pair of suits that the law is unconstitutional.

  • August 10, 2026

    Welch Allyn, IRhythm Reach Deal To End Patent Dispute

    Welch Allyn Inc. has entered a deal to bring a close to a lawsuit in Delaware federal court accusing iRhythm Technologies Inc. of infringing a series of heart monitor patents after iRhythm had its attempts to challenge some of those patents shot down.

  • August 10, 2026

    Tax Man Who Shaved Insurance Crook's Income Gets 2 Years

    A Manhattan federal judge has sentenced a preparer of fraudulent tax returns to two years in prison after prosecutors said his cooperation against a client who operated a bribery-fueled insurance scam was marred by confusing proffers and altered records.

  • August 10, 2026

    H.I.G. Can't Block Calif. Suit Over $17.5M Health Deal

    The Delaware Chancery Court on Monday refused to block two former behavioral health facility owners from pursuing a California securities fraud suit against private equity firm H.I.G. Capital LLC and its affiliates, finding the companies had not shown the dispute must be litigated in Delaware.

  • August 10, 2026

    Arkansas Medical System Escapes Target-Date 401(k) Suit

    An Arkansas federal judge on Monday dismissed a proposed class action alleging Arkansas medical system Washington Regional mismanaged the system's employee 401(k) plan, holding that allegations of underperforming investment funds weren't backed up with enough comparisons to better-performing ones to state a claim for violating federal benefits law.

  • August 10, 2026

    11th Circ. Affirms Ga. University System's Win In Bias Suit

    The Eleventh Circuit on Monday upheld a win for the University System of Georgia in a disability discrimination case brought by a former respiratory therapy student who alleged he was improperly found to be endangering patients' safety and given a failing grade as punishment.

  • August 10, 2026

    Alto Neuroscience Escapes Investor Drug Trial Suit, For Now

    Alto Neuroscience has escaped a shareholder suit alleging the psychiatric biotech company and its top brass overstated the efficacy of their lead drug candidate for treating major depressive disorder, with a California federal judge ruling that the suit's "vague and conclusory" pleadings should be remedied.

  • August 10, 2026

    8th Circ. Nixes Native American Worker's Race Bias Suit

    The Eighth Circuit on Monday upheld a clinical research institute's defeat of a lawsuit from a former manager who said she was laid off because she's Native American, siding with the institute's assertion that she was let go for budgetary reasons because her position was funded with internal money.

  • August 10, 2026

    Judge Trims BCBS Privacy Suit Over Public Site Data

    Blue Cross Blue Shield Association beat most claims in a proposed privacy class action Friday when an Illinois federal judge ruled that federal employees' searches for doctors, symptoms and medical conditions on its public website did not amount to protected health information.

  • August 10, 2026

    Mass. Court Says Insurer Must Defend Doctor In Stalking Case

    Massachusetts' highest court has ruled that an insurance company must defend a doctor in disciplinary proceedings for allegedly stalking and harassing a patient to whom he prescribed an addictive medication for several years.

  • August 10, 2026

    Northwestern To Pay $4M In COVID-Era Tuition Refunds

    Northwestern University is set to pay $4 million to settle students' pursuit of refunds after the COVID-19 pandemic forced class instruction online, which the students alleged violated their agreement with the university.

  • August 10, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court last week tackled disputes involving merger settlements, contract claims, controlling stockholders, music rights, prejudgment interest, absentee voting and stockholder standing.

  • August 10, 2026

    Jazz Pharma Buying Actio In Up To $1.32B Epilepsy Push

    Dublin-based Jazz Pharmaceuticals PLC said Monday it will pay up to $1.32 billion for privately held Actio Biosciences, with Hogan Lovells Cadwalader advising Jazz and Cooley LLP guiding Actio. 

  • August 10, 2026

    3 Firms Guide Teledyne's $1.1B Varex Imaging Deal

    Teledyne Technologies Inc. said Monday it has agreed to purchase Varex Imaging Corp. in a deal valued at about $1.1 billion, with Latham & Watkins LLP and McGuireWoods LLP advising Teledyne and Orrick Herrington & Sutcliffe LLP representing Varex.

  • August 07, 2026

    Carradine Family Says UCLA Ignored Suicide Watch Rules

    The family of Robert Carradine sued the Regents of the University of California Friday in Los Angeles court, alleging the actor's death after a suicide attempt while in a UCLA facility came because staff ignored several key policies about patients on suicide watch.

  • August 07, 2026

    Taco Bell, Taylor Farms Sued Over Tainted Lettuce

    A Florida consumer hit Taco Bell and Taylor Farms with a proposed class action Thursday over the ongoing cyclospora outbreak caused by contaminated lettuce, which so far has affected thousands of people in multiple states and been linked to two deaths.

  • August 07, 2026

    VA To Test Psilocybin For Veterans With Severe Depression

    Former military service members in five U.S. cities will have an opportunity to treat their depression with psilocybin through a clinical trial being run by the U.S. Department of Veterans Affairs, according to an agency announcement.

  • August 07, 2026

    Texas Docs Can't Exit Patient's Hernia Surgery Death Suit

    A Texas appellate court has refused to toss a suit accusing two doctors of causing a hernia surgery patient's death, finding that the plaintiff submitted an expert report that met the "low threshold" required under the state's medical malpractice statute.

  • August 07, 2026

    Fired Doc, Fla. Hospital Strike Deal In Age Bias Suit

    A Florida doctor has settled an age discrimination suit against a hospital that he claimed abruptly pulled a contract renewal and replaced him with a much younger doctor.

  • August 07, 2026

    Glenmark's $29.6M Generics Price-Fixing Deal Gets 1st OK

    A Connecticut federal court on Thursday gave a preliminary OK to a settlement between a coalition of 48 states and territories and drugmaker Glenmark Pharmaceuticals Ltd. that would pay out more than $29.6 million in restitution to eligible consumers and the coalition.

Expert Analysis

  • AI Due Diligence Is Key For Healthcare M&A

    Author Photo

    As usage of artificial intelligence in healthcare continues to rise, the due diligence landscape for healthcare mergers and acquisitions demands attention to risks that frameworks from even just a few years ago were not designed to catch, say attorneys at Husch Blackwell.

  • Bracing For Enforcers' Growing Focus On Behavioral Health

    Author Photo

    While recent law enforcement scrutiny of the behavioral health industry has resulted in several settlements, indicating that more enforcement activity is on the way, organizations now have an opportunity to take proactive compliance measures, says Jeffrey Fitzgerald at Polsinelli.

  • Sizing Up The Rescheduling Hurdles Medical Pot Cos. Face

    Author Photo

    The Justice Department’s recent lowering of certain medical marijuana products to Schedule III means operators — particularly those simultaneously offering federally illegal adult-use cannabis — must implement greater structural discipline to navigate an increasingly fragmented legal landscape if they hope to benefit from new tax deductions and access to capital, say attorneys at Akerman.

  • DOJ Activity Indicates Rising Antitrust Risk For Hospitals

    Author Photo

    Two civil actions filed by the U.S. Department of Justice against New York-Presbyterian Hospital and OhioHealth, both alleging that the hospital systems used their market power to stifle competition, highlight the government's growing scrutiny of barriers to lower-cost insurance options, say attorneys at Freshfields.

  • Class Actions At The Circuit Courts: May Lessons

    Author Photo

    In this month's review of class action appeals, Mitchell Engel at Shook Hardy discusses four recent rulings from cases involving allegations of Title VII violations, the Employment Retirement Income Security Act, prison dental care violations and overcharging for PACER access.

  • Series

    NY Times Word Puzzles Make Me A Better Lawyer

    Author Photo

    Every morning I let The New York Times humble me with word games, which offer a chance to recalibrate my brain before the day's chaos arrives and remind me that a solution — whether to a puzzle or employment law issue — almost always exists once I find the right angle, says Amy Epstein Gluck at Pierson Ferdinand.

  • Engaging With FDA's New Complete Response Letter Policy

    Author Photo

    A citizen petition filed with the U.S. Food and Drug Administration last month puts renewed focus on the agency's practice of releasing complete response letters in near real time, materially altering the context in which life sciences companies communicate with investors regarding regulatory developments, say attorneys at Debevoise.

  • Tracking Tech Suit Is A Risk Management Reminder For Cos.

    Author Photo

    The Fifth Circuit recently heard oral argument in Rand v. Eyemart Express — an appeal that could reshape the legal landscape for businesses that deploy tracking tech on their websites — underscoring the importance of proactive risk management for companies across multiple industries, say attorneys at Blank Rome.

  • Series

    Law School's Missed Lesson: Diagnose Before Arguing

    Author Photo

    Law school often skips over explicitly teaching students how to determine what kind of problem a case presents before they commit to a particular doctrinal path, which risks building arguments that are internally coherent but externally misaligned, says Melanie Oxhorn at Kobre & Kim.

  • Trump's Psychedelics EO Creates A Regulatory Collision

    Author Photo

    Sponsors pursuing U.S. Food and Drug Administration approval for psychedelic drug access must tackle how to generate regulatory-grade safety and efficacy data in controlled trials when President Donald Trump's recent executive order on psychedelics mandates uncontrolled access through Right to Try, say Kimberly Chew at Husch Blackwell and Odette Hauke at Odette Alina.

  • Becoming The Biz-Savvy GC That Portfolio Companies Need

    Author Photo

    Candidates for general counsel roles at private equity-backed portfolio companies should prioritize proving their sector-specific experience, commercial judgment and ease with uncertainty — and attorneys hoping to be candidates in five to 10 years should start working on those skills now, says Dimitri Mastrocola at Major Lindsey.

  • AI Regulatory Gaps May Fuel FCA Enforcement Action

    Author Photo

    The intersection of artificial intelligence and False Claims Act enforcement presents legal risk for government contractors across several industries, particularly in the absence of a federal regulatory framework explicitly governing its development and use, say attorneys at O’Melveny.

  • Series

    Judges On AI: How Courts Can Survive The Tech Revolution

    Author Photo

    Colorado Supreme Court Justice Maria Berkenkotter and Colorado Court of Appeals Judge Lino Lipinsky de Orlov discuss how artificial intelligence has already fundamentally altered the legal system and offer tips for courts navigating deepfakes, hallucinations and a gap in access to AI tools.

  • 'Skinny Label' Arguments Spotlight Induced Infringement Risk

    Author Photo

    Recent oral arguments before the U.S. Supreme Court in Hikma Pharmaceuticals v. Amarin Pharma highlight the uncertain boundary between lawful generic competition through so-called skinny labels and induced patent infringement, with potential implications for patent holders’ communication, enforcement and causation strategies across industries, says Anton Hopen at Trenam.

  • 3 AI Adoption Mistakes GCs Should Avoid

    Author Photo

    The pressure in-house legal teams face to quickly adopt artificial intelligence tools, combined with budget constraints and the need to evaluate a crowded market of options, sets the stage for implementation mistakes that are often difficult to undo, says former 23andMe general counsel Guy Chayoun.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Health archive.